Investment analysts at Guggenheim began coverage on shares of Pyxis Oncology (NASDAQ:PYXS - Get Free Report) in a report released on Wednesday, Marketbeat.com reports. The firm set a "buy" rating on the stock.
A number of other brokerages have also weighed in on PYXS. Wall Street Zen raised shares of Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 24th. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Finally, Zacks Research upgraded shares of Pyxis Oncology from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $7.75.
Read Our Latest Research Report on Pyxis Oncology
Pyxis Oncology Trading Up 18.6%
Shares of NASDAQ:PYXS opened at $1.91 on Wednesday. The company has a 50 day moving average of $1.21 and a 200-day moving average of $1.16. The firm has a market cap of $118.46 million, a P/E ratio of -1.19 and a beta of 1.14. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.39.
Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The company had revenue of $2.82 million during the quarter. Equities research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.
Hedge Funds Weigh In On Pyxis Oncology
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock valued at $84,000 after buying an additional 9,062 shares in the last quarter. Barclays PLC boosted its position in Pyxis Oncology by 20.2% in the fourth quarter. Barclays PLC now owns 77,013 shares of the company's stock valued at $121,000 after buying an additional 12,924 shares in the last quarter. ProShare Advisors LLC acquired a new position in Pyxis Oncology in the fourth quarter valued at about $26,000. Jane Street Group LLC raised its stake in shares of Pyxis Oncology by 36.6% in the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock worth $106,000 after acquiring an additional 18,128 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Pyxis Oncology in the fourth quarter worth about $35,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.
About Pyxis Oncology
(
Get Free Report)
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Read More
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
